Medasense

Ramat Gan, Israel All Israel companies → — Founded 2008

Medical Device / Hardware Specialty-Focused AI

Series C

Website Claim this company

Products

PMD-200

Medasense

Clinical Decision Support & Reference

Medasense PMD-200 is an FDA-authorized AI-driven medical device that objectively quantifies a patient's physiological pain response (nociception) using the NOL Index, primarily for anesthetized patients in operating rooms and critical care.

See all 1 product →

About Medasense

Medasense is a medical technology company that has developed an AI-powered platform to objectively quantify pain, particularly in patients who cannot communicate their pain levels. Their flagship product, the PMD-200™ with its Nociception Level (NOL®) technology, uses a non-invasive finger probe to collect physiological data such as heart rate, heart rate variability, skin conductance, and temperature. This data is then analyzed by artificial intelligence algorithms to generate a single, easy-to-interpret score (NOL index) from 0 (no pain) to 100 (extreme pain).

This objective measurement aims to guide clinicians in administering analgesics, preventing both under- and over-medication, and their associated complications. The PMD-200™ is primarily used in operating rooms and critical care settings, where patients are under anesthesia or otherwise unable to communicate their pain. Medasense’s technology has received regulatory approvals, including the CE Mark in Europe in 2017 and De Novo marketing authorization from the U.S. FDA in February 2023, enabling its commercialization in various global markets.

Medasense is also developing pipeline products, such as NOLedge™, for use in clinics and home care settings. These advancements aim to lead pain prediction, stratification, and prevention strategies, further transforming pain assessment and treatment worldwide. The company’s mission is to personalize and optimize pain management, reduce patient suffering, avoid overmedication, and lower healthcare costs.

Focus Areas

objective pain monitoring personalized pain management AI in healthcare non-invasive sensing nociception assessment critical care operating room solutions

Business Intelligence

Technology

AI operating system, cloud-native, non-invasive sensor platform

What Physicians Need to Know

Objective Pain Monitoring

Medasense specializes in objective pain monitoring through its Nociception Level (NOL) technology. This technology quantifies a patient's physiological response to pain (nociception) in real-time, continuously, and non-invasively. It addresses the limitations of subjective pain assessments and indirect measures like heart rate and blood pressure, which are often unreliable in anesthetized or critical care patients.

Personalized Pain Management

Medasense's NOL technology enables personalized pain management by providing clinicians with objective data to titrate analgesics to a patient's specific needs. This helps optimize treatment, avoid over- or under-medication, and potentially reduce opioid consumption and associated complications.

AI in Healthcare

Medasense leverages proprietary artificial intelligence (AI) technology and machine learning algorithms to analyze a constellation of nociception-related physiological responses. This AI-driven approach creates a unique pain signature for each patient, allowing for a personalized understanding of their pain response.

Non-Invasive Sensing

The company's core technology relies on a non-invasive sensor platform, typically a finger probe, to acquire physiological signals. This approach ensures patient comfort and safety while providing continuous monitoring.

Nociception Assessment

Medasense's NOL index is a multiparameter composite of autonomic signals that reflects the balance between nociception (physiological response to noxious stimuli) and anti-nociception. It provides a more reliable and specific assessment of nociception compared to traditional methods.

Critical Care Solutions

Medasense's flagship product, the PMD-200™, is designed for use in critical care settings and operating rooms. It visualizes pain response and helps manage pain in patients who are unable to communicate their discomfort, such as those under general anesthesia or sedation.

Operating Room Solutions

The PMD-200™ with NOL technology is specifically utilized in operating rooms to guide analgesic dosing during surgery. Studies have shown that NOL-guided analgesia can lead to a significant reduction in postoperative pain, fewer hypotensive events, and potential cost savings.

Physician Tip

Medasense's NOL technology offers physicians a crucial decision support tool for objectively assessing and optimizing pain treatment, particularly in patients unable to self-report pain. By providing real-time, objective data on nociception levels, it enables personalized analgesic dosing, potentially reducing postoperative pain by up to 33% and lowering opioid consumption. This can lead to improved patient safety, better outcomes, and reduced healthcare costs by minimizing complications associated with over- or under-medication. The PMD-200™ device is non-invasive, continuous, and easy to use, integrating with existing patient monitors. Physicians should interpret the NOL trend in conjunction with other clinical judgments and vital signs.

Medasense's PMD-200™ can operate as a standalone device or connect with patient monitors from companies like Philips and Mindray. The company is also working on making pain monitoring data available in hospital EHRs through Philips Capsule. Medasense is expanding its offerings with pipeline products like NOLedge™, a cloud-based platform for agile pain-related insights in clinics and home care, which aims to transform physiological data from multiple sources into actionable insights.

Products by Medasense

1 product in the directory

PMD-200

Medasense

Clinical Decision Support & Reference

What the Web Says

Medasense is a medical device company that has developed the NOL (Nociception Level) technology, which uses AI and a non-invasive sensor platform to objectively monitor and quantify a patient's pain response. This technology, particularly its flagship product PMD-200™, is used in critical care and operating rooms to personalize pain management, optimize treatment, and avoid overmedication, especially for patients unable to communicate their pain. Clinical studies have shown that NOL monitoring can reduce postoperative pain and potentially decrease healthcare costs.

Overall: Positive

Strengths

Objectively monitors and quantifies pain response using AI and a non-invasive sensor platform.
Enables personalized pain management and helps avoid overmedication.
Reduces postoperative pain and can lead to decreased healthcare costs.
FDA marketing authorization for PMD-200™ with NOL technology.
Integrates with patient monitors from companies like Philips and Mindray.
Strong clinical evidence supporting its impact on patient safety and outcomes.

Limitations

No specific cons were found in the provided search results regarding Medasense's products or as an employer.
Limited information available on employee reviews from Glassdoor or Reddit.
No reviews found on G2 or Capterra specifically for Medasense products, though these platforms do host reviews for other healthcare software.

Based on reviews from: medasense.com, aviahealth.com, medicalbuyer.co.in, medicaldesignandoutsourcing.com, mpo-mag.com, prnewswire.com, eurekalert.org, firstwordhealthtech.com, indeed.com, simplyhired.com, capterra.com, g2.com, newswire.ca

Last updated: 2026-10-28

Videos

News, demos, and interviews about Medasense.

Loading videos...

Videos load interactively. If none appear, search YouTube for Medasense →

View all on YouTube

Press & Coverage

einpresswire.com

Medasense Biometrics Receives Innovative Technology Contract from Vizient® for PMD-200™ with NOL Technology

Medasense's PMD-200™ pain response (nociception) monitoring system with NOL technology has received an Innovative Technology contract from Vizient®, the largest provider-driven healthcare performance improvement company in the U.S. This contract highlights the potential of Medasense's AI-powered NOL technology to revolutionize pain monitoring for improved patient care.

2026-08

medasense.com

Pain Monitoring Data to be Available in Hospital EHRs through Philips Capsule

Medasense announced that pain monitoring data will be integrated into hospital Electronic Health Records (EHRs) through Philips Capsule. This integration aims to enhance data accessibility and streamline pain management practices within healthcare facilities.

2026-07

medasense.com

Medasense and Jefferson Health to Collaborate on Study of Pain Monitoring Technology in Spine Surgery

Medasense is collaborating with the Department of Anesthesiology and Perioperative Medicine at Thomas Jefferson University on a clinical trial. The study will examine the use of Medasense's Nociception Level Index (NOL) technology during spine surgery procedures to personalize analgesic dosing.

2026-03

nsmedicaldevices.com

Medasense secures FDA approval for PMD-200 monitor with NOL technology

Medasense Biometrics received US Food and Drug Administration (FDA) marketing authorization for its PMD-200 patient monitor with NOL technology through the De Novo premarket review pathway. This approval allows Medasense to offer the first and only measure of intraoperative pain (nociception) in the US, aiming to improve pain-related outcomes for surgical patients.

2023-02

medasense.com

FDA Commissioner Highlights Marketing Authorization of NOL Technology

FDA Commissioner Robert M. Califf, MD, highlighted the marketing authorization of NOL technology as an innovative solution for clinicians to personalize opioid-based analgesia in anesthetized patients. This recognition underscores the potential of Medasense's technology in combating harm from opioids.

2023-09

eurekalert.org

Reduced postoperative pain in patients receiving nociception monitor guided analgesia during elective major abdominal surgery: a randomized, controlled trial.

A peer-reviewed randomized, controlled study published in the Journal of Clinical Monitoring and Computing found that monitoring pain response levels during surgery with Medasense's NOL technology can reduce postoperative pain by 30-33%. The study demonstrated that NOL-guided fentanyl dosing led to lower pain scores in the post-anesthesia care unit.

2022-09

medasense.com

Study Explores the Ability of NOL Technology to Detect Pain in the ICU

A peer-reviewed observational study published in the Journal of Pain Research revealed promising findings regarding Medasense's NOL monitor's ability to detect pain response levels in ICU patients. The study showed that NOL could detect pain during chest tube removal, correlating with patient's self-reported pain levels, suggesting its potential to optimize pain management in the ICU.

2022-01

medasense.com

Medasense Raises $18M in Series C Round

Medasense Biometrics raised $18 million in a Series C funding round from Sabadell Asabys venture capital firm, Israeli family offices, and returning investors. The funding is intended to expand commercial deployment of NOL technology in Europe and to complete the process of obtaining FDA approval for commercialization in the U.S.

2020-09

Frequently Asked Questions

What is Medasense's core technology for objective pain monitoring and how does it work?

Medasense's core technology is the Nociception Level (NOL) index, which objectively quantifies a patient's physiological response to pain (nociception) in real-time. It uses a non-invasive finger probe to collect multiple physiological signals, which are then analyzed by AI-powered algorithms to provide a continuous, numeric score (0-100) representing the patient's nociception level.

How does Medasense's technology contribute to personalized pain management and the use of AI in healthcare?

Medasense's technology enables personalized pain management by providing clinicians with objective data on a patient's individual pain response, even when the patient cannot communicate. The AI-driven algorithms analyze physiological parameters to create a unique pain signature for each patient, allowing for tailored analgesic dosing and helping to avoid over- or under-medication.

What are Medasense's main products and their applications in critical care and operating room settings?

Medasense's flagship product is the PMD-200™ patient monitor, which utilizes NOL technology. It is designed for use in operating rooms and critical care settings where patients are under general anesthesia or otherwise unable to communicate their pain. The PMD-200™ helps clinicians assess nociception and objectively titrate analgesics, aiming for smoother procedures, improved patient safety, and better outcomes.

What is the regulatory status and compliance of Medasense's products, particularly in key markets?

Medasense's PMD-200™ with NOL technology has received marketing authorization from the U.S. FDA through the De Novo premarket review pathway, making it the first and only FDA-authorized monitor for nociception in adult patients under general anesthesia in the United States. It also has CE mark approval for commercial availability in Europe, Canada, South Africa, UAE, Israel, and select Latin American countries.

What kind of support and partnerships does Medasense offer to healthcare providers and institutions?

Medasense provides customer support for its products, including user manuals and technical assistance. The company has established strategic partnerships for distribution and collaboration, including agreements with Medtronic in Europe and Israel, Nihon Kohden in Japan, and Panakeia, LLC for U.S. government institutions. Medasense also collaborates with institutions like Thomas Jefferson University on clinical trials.

What is Medasense's company stability and funding status?

Medasense Biometrics was founded in June 2008. The company has raised a total of $33.5 million across 5 funding rounds from 9 investors. Their latest funding round was a Series C in September 2020, raising $18 million. Investors include Baxter Ventures, Olive Tree Ventures, and Sabadell Asabys venture capital firm.

Related Companies

Suggest an Edit → | Report an issue